Should You Consider Buying, Selling, or Keeping UiPath Shares Ahead of Q4 Results?
UiPath Set to Announce Q4 Fiscal 2026 Results
UiPath Inc. (PATH) is scheduled to release its fourth-quarter fiscal 2026 financial results after market close on March 11.
Analysts currently expect the company to report earnings of $0.25 per share for the quarter, reflecting a 3.9% decrease compared to the same period last year. Revenue is projected to reach $464.9 million, representing a 9.7% increase year over year. Over the past two months, one analyst has raised their earnings estimate, while no downward revisions have been made.
Image Source: Zacks Investment Research
UiPath has a strong history of outperforming earnings expectations, having exceeded consensus estimates in each of the last four quarters with an average surprise of 42.4%.
Will PATH Beat Q4 Earnings Expectations?
According to current models, there is no clear indication that PATH will surpass earnings estimates this quarter. Typically, a combination of a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), #2 (Buy), or #3 (Hold) increases the likelihood of an earnings beat. However, PATH currently holds an Earnings ESP of 0.00% and a Zacks Rank #3, which does not suggest a strong chance of beating expectations.
Subscription Revenue Expected to Drive Growth
For the fourth quarter, subscription services are anticipated to be the main growth engine, with consensus estimates placing subscription revenue at $251 million—a 16.6% increase from the previous year. License revenue is forecasted at $201.7 million, up 2% year over year, while professional services and other revenue are expected to total $12.2 million, marking a 12.3% annual rise.
Recent Stock Performance
Over the past three months, PATH shares have dropped by 37%, compared to a 12% decline in the broader industry and a 2.5% decrease in the Zacks S&P 500 composite. The company’s forward price-to-earnings ratio stands at 15.44, which is significantly lower than the industry average of 28.34.
Image Source: Zacks Investment Research
Key Factors for Investors to Consider
UiPath continues to solidify its leadership in automation and AI software through effective execution and expanding alliances. In the most recent quarter, the company reported robust revenue growth and higher annual recurring revenue, indicating sustained enterprise demand for its automation solutions. UiPath also achieved its first GAAP-profitable third quarter, underscoring the scalability of its software-centric business model.
Growth is being fueled by the adoption of UiPath’s unified agentic automation platform, which integrates automation, AI agents, and orchestration into a single, managed environment. Strategic partnerships with industry leaders such as Microsoft, Alphabet’s Google, and NVIDIA are expanding UiPath’s ecosystem. These collaborations enhance workflow automation, strengthen AI capabilities, and support advanced AI deployment, helping UiPath maintain its edge as enterprises accelerate their automation initiatives.
Investor Strategy Ahead of Earnings
Given the current environment, a cautious approach may be wise for those considering UiPath before its earnings release. The company benefits from growing enterprise demand and strategic partnerships, which support long-term innovation. However, recent share price weakness and uncertainty about near-term earnings momentum suggest that investors should be prudent. Existing shareholders might choose to hold their positions and monitor the upcoming results and management commentary, while new investors may want to wait for more clarity after the earnings announcement.
PATH holds a Zacks Rank #3 (Hold).
5 Stocks Poised for Significant Gains
Zacks experts have identified five stocks with the potential to double in value over the next year. While not every pick will be a winner, previous selections have achieved gains of +112%, +171%, +209%, and +232%.
Many of these stocks remain largely unnoticed by Wall Street, offering investors a unique opportunity to get in early.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
INCY Receives European Commission Authorization to Broaden Zynyz Oncology Drug Indication

Q4 Top Performers: Labcorp (NYSE:LH) and Other Leading Testing & Diagnostics Services Stocks
Nvidia's $30B OpenAI Bet: The Final Pre-IPO Call Before Strategic Lock-In Ends
Long-Term Bitcoin Trader: The Great XRP Reset Has Been Completed. What Does It Mean?
